Article Categories
Allergy and Immunology
Cardiology
Clinical Procedures
Critical Care
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genomic Medicine
Hematology
Infectious Diseases
Nephrology
Neurology
Obstetrics and Gynecology
Oncology
Pathology
Perioperative Care
Physical & Rehabilitation
Psychiatry
Pulmonology
Radiology
Rheumatology
Sports Medicine
Browse Categories
Browse Drugs
Browse Journals
Search
Browse Categories
Browse Categories
Allergy and Immunology
Cardiology
Clinical Procedures
Critical Care
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genomic Medicine
Hematology
Infectious Diseases
Nephrology
Neurology
Obstetrics and Gynecology
Oncology
Pathology
Perioperative Care
Physical & Rehabilitation
Psychiatry
Pulmonology
Radiology
Rheumatology
Sports Medicine
Browse Journals
Publications by authors named "Adele Hobbs-Muthukumar"
Page
1
of
1
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Alain P Algazi
Rosaura Esteve-Puig
Adi Nosrati
Brian Hinds
Adele Hobbs-Muthukumar
Pigment Cell Melanoma Res
January 2018
Article Synopsis
Scientists studied how certain pathways in the body might cause serious skin cancer in patients with specific gene mutations (NRAS and BRAF).
Patients were given two medicines, trametinib and GSK2141795, to see if they would help, but the results showed no improvements in their cancer.
Most patients had some bad side effects, like rashes, but the study concluded that this treatment doesn't work well for these types of melanoma.
View Article and Find Full Text PDF
Privacy Policy
Site Map
Contact Us
© LitMetric 2025. All rights reserved.